Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dornase alfa.

P L Shah1, M E Hodson

  • 1Department of Cystic Fibrosis, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, London, England.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 23, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biodegradable microplastics adsorb more Cd than conventional microplastic and biofilms enhance their adsorption.

Chemosphere·2025
Same author

Microplastics and metals: Microplastics generated from biodegradable polylactic acid mulch reduce bioaccumulation of cadmium in earthworms compared to those generated from polyethylene.

Ecotoxicology and environmental safety·2024
Same author

Survival following lung volume reduction procedures: results from the UK Lung Volume Reduction (UKLVR) registry.

BMJ open respiratory research·2024
Same author

Size- and concentration-dependent effects of microplastics on soil aggregate formation and properties.

Journal of hazardous materials·2024
Same author

Ethanol, not water, should be used as the dispersant when measuring microplastic particle size distribution by laser diffraction.

The Science of the total environment·2023
Same author

Position statement on endoscopic lung volume reduction in South Africa: 2022 update.

African journal of thoracic and critical care medicine·2022
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Dornase alfa (recombinant human deoxyribonuclease) thins mucus in cystic fibrosis patients, improving lung function and reducing infections. Treatment response varies, but compliant patients with purulent sputum are candidates.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Biochemistry

Background:

  • Cystic fibrosis (CF) involves chronic lung infections and mucus buildup.
  • Current therapies aim to improve airway secretion clearance.
  • Extracellular DNA contributes to sputum viscosity in CF patients.

Purpose of the Study:

  • To evaluate the efficacy of dornase alfa in managing cystic fibrosis.
  • To investigate the impact of dornase alfa on pulmonary function and exacerbations.
  • To explore patient selection criteria for dornase alfa therapy.

Main Methods:

  • Dornase alfa (recombinant human deoxyribonuclease) administered via aerosolized inhalation.
  • Dosage: 2.5mg once daily.
  • Clinical trials assessed pulmonary function and respiratory exacerbations.

Related Experiment Videos

Main Results:

  • Dornase alfa reduces sputum viscoelasticity by depolymerizing extracellular DNA.
  • The drug improves lung function and decreases the risk of infectious exacerbations.
  • Treatment response is heterogeneous, with some patients benefiting from reduced exacerbations rather than improved lung function.

Conclusions:

  • Dornase alfa is a potential therapy for cystic fibrosis patients with purulent sputum.
  • Patient selection should consider compliance and be monitored closely for treatment response.
  • Treatment decisions should be individualized, irrespective of disease severity, focusing on clinical benefit.